Design of ProCAs (Protein‐Based Gd3+ MRI Contrast Agents) with High Dose Efficiency and Capability for Molecular Imaging of Cancer Biomarkers

@article{Xue2014DesignOP,
  title={Design of ProCAs (Protein‐Based Gd3+ MRI Contrast Agents) with High Dose Efficiency and Capability for Molecular Imaging of Cancer Biomarkers},
  author={Shenghui Xue and Jingjuan Qiao and Jie Jiang and Kendra Hubbard and Natalie White and Lixia Wei and Shun-yi Li and Zhi-Ren Liu and Jenny J. Yang},
  journal={Medicinal Research Reviews},
  year={2014},
  volume={34}
}
Magnetic resonance imaging (MRI) is the leading imaging technique for disease diagnostics, providing high resolution, three‐dimensional images noninvasively. MRI contrast agents are designed to improve the contrast and sensitivity of MRI. However, current clinically used MRI contrast agents have relaxivities far below the theoretical upper limit, which largely prevent advancing molecular imaging of biomarkers with desired sensitivity and specificity. This review describes current progress in… 

Signal Intensity Analysis of Novel Protein-based MRI Contrast Agents

Statistically significant results suggest that ProCA1B14 has the great potential to be a tumor specific contrast agent and ProCA32 could be a promising MRI contrast agent for the liver imaging in clinical applications.

MRI Signal Intensity Analysis of Novel Protein-based MRI Contrast Agents

Statistically significant results suggest that ProCA1B14 has the great potential to be a tumor specific contrast agent and ProCA32 could be a promising MRI contrast agent for the liver imaging in clinical applications.

Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.

This effort in further developing biomarker-targeted protein MRI contrast agents for molecular imaging of PSMA is reported, which enables the first MRI enhancement dependent on PSMA expression levels in tumor bearing mice using both T1 and T2-weighted MRI at 7 T.

Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging

Using T1- and T2-weighted, as well as T2/T1 ratio imaging, this work achieves robust MRI detection of early liver metastases as small as ∼0.24 mm in diameter, much smaller than the current detection limit of 10–20 mm.

Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

This comprehensive review describes the state of the art of clinically approved contrast agents, their mechanism of action, and factors influencing their safety and efforts to make safer contrast agents either by increasing relaxivity, increasing resistance to metal ion release, or by moving to gadolinium(III)-free alternatives.

Targeted Contrast Agents for Molecular MRI

This review focuses on gadolinium-based specific-targeted contrast agents, providing rational design considerations and examples of the strategies recently reported in the literature.

Protein Modification of Designed MRI Contrast Agents

The aim of this thesis is to develop a novel protein modification on ProCA by glycosylation to improve liver distribution by targeting liver receptor, asialoglycoprotein receptor (ASGPR).

Lumazine Synthase Protein Nanoparticle-Gd(III)-DOTA Conjugate as a T1 contrast agent for high-field MRI

The findings suggest that Gd(III)-DOTA-AaLS-R108C could serve as a potential theranostic nanoplatform at high magnetic field strength.

Designing Calcium-Binding Proteins for Molecular MR Imaging.

Criteria for the design and engineering of calcium-binding protein (CaBP) parvalbumin as a protein Gd-MRI contrast agent (ProCA) with unprecedented metal selectivity for Gd3+ over physiological metal ions is introduced.

GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI

The development of a GRPR-targeted MRI contrast agent is reported by grafting the GRPR targeting moiety into a scaffold protein with a designed Gd3+ binding site (ProCA1.GRPR) that enables in vivo detection of GRPR expression and spatial distribution in both PC3 and H441 tumors in mice using MRI.

References

SHOWING 1-10 OF 196 REFERENCES

Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.

This paper focuses on reporting the current progress on designing a novel class of protein-based Gd(3+) MRI contrast agents (ProCAs) equipped with several desirable capabilities for in vivo application of MRI of tumor biomarkers.

Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.

  • P. Caravan
  • Biology, Chemistry
    Accounts of chemical research
  • 2009
It is found that, while protein binding generally improves relaxivity by slowing the tumbling rate of the complex, in some cases, the protein itself can also negatively affect hydration of the metal complex and/or inner-sphere water exchange.

HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent

A novel MR imaging probe targeting to HER2, a biomarker for various cancer types and a drug target for anti-cancer therapies, is developed that integrates a de novo designed protein contrast agent with a high affinity HER2 affibody and a near IR fluorescent dye.

Protein-Based MRI Contrast Agents for Molecular Imaging of Prostate Cancer

Protein-based MRI contrast agent with tumor targeting modality can specifically target GRPR-positive prostate cancer and provides high-sensitivity MR imaging in tumor cells and mouse models.

Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents

The noninvasive capability of MRI to visualize spatially and temporally the intratumoral distribution as well as quantify the levels of EGFR and HER2 would greatly improve the ability to track changes of the biomarkers during tumor progression, monitor treatment efficacy, aid in patient selection, and further develop novel targeted therapies for clinical application.

A Gd3+-based magnetic resonance imaging contrast agent sensitive to beta-galactosidase activity utilizing a receptor-induced magnetization enhancement (RIME) phenomenon.

The design and synthesis of a novel beta-galactosidase-activated MRI contrast agent, the Gd(3+) complex [Gd-5], is described by using the RIME approach, which exhibited a 57% increase in the r(1) relaxivity in phosphate-buffered saline (PBS) with 4.5% w/v human serum albumin (HSA) in the presence of beta-GalactosIDase.

Rational design of protein-based MRI contrast agents.

The rational design of a novel class of magnetic resonance imaging (MRI) contrast agents with engineered proteins chelated with gadolinium is described, which exhibit much stronger contrast enhancement and much longer blood retention time than Gd-DTPA in mice.

Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI

Quantification of the signal from cell monolayers imaged at 1.5 T demonstrated, as predicted via modeling, that only picomolar concentrations of paramagnetic perfluorocarbon nanoparticles were required for the detection and quantification of tissue factor at clinical field strengths.

Responsive MRI agents for sensing metabolism in vivo.

This review describes examples of imaging extracellular pH in brain tumors, ischemic hearts, and pancreatic islets with Gd(3+)-based pH sensors and discusses the potential of CEST and PARACEST agents as metabolic imaging sensors.
...